Pyrrolopyrimidine comprising cyclopentyl substituent
A pyrrolopyrimidine comprising a cyclopentyi substituent. The present invention specifically relates to a compound represented by formula. A and a stereoisomer and pharmaceutically acceptable salt thereof. The invention further relates to a method for manufacturing the pyrrolopyrimidine comprising the cyclopentyl substituent represented by formula A, a pharmaceutical composition, and an application of the compound in treating a disease induced by Janus kinase.
1. A compound represented by formula A, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
wherein R 1 and R 4 are each independently selected from the group consisting of H, hydroxyl, and oxo; and R 2 and R 3 are each independently selected from the group consisting of H, and oxo; with the proviso that R 1 , R 2 , R 3 , and R 4 are not all H.
2. The compound represented by formula A according to claim 1 , wherein R 1 and R 2 are both H.
3. The compound represented by formula A according to claim 1 , wherein one of R 3 and R 4 is H, and the other is hydroxyl or oxo.
4. The compound according to claim 1 , wherein the compound is selected from the group consisting of:
5. A pharmaceutical composition, comprising the compound according to claim 1 , a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients.
6. A pharmaceutical composition, comprising the compound according to claim 4 , a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients.
7. A method for treating a disease mediated by Janus kinase, comprising administering to a patient a therapeutically effective amount of the compound according to claim 1 , a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the disease mediated by Janus kinase is lymphoma or leukemia.
8. The method according to claim 7 , further comprising administering to a patient one or more pharmaceutically acceptable carriers or excipients.
9. A method according to claim 7 , wherein the compound is selected from the group consisting of:
or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
10. The method according to claim 9 , further comprising administering one or more pharmaceutically acceptable carriers or excipients.
11. A method for inhibiting Janus kinase, comprising administering an effective amount of the compound according to claim 1 .
12. The method according to claim 11 , further comprising administering one or more pharmaceutically acceptable carriers or excipients.
13. The method according to claim 11 , wherein the compound is selected from the group consisting of:
or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
14. The method of claim 13 , further comprising administering one or more pharmaceutically acceptable carriers or excipients.